|
RTW Venture Fund Ltd - New York-based investor in life sciences, biopharmaceutical, and medical technology companies - Portfolio firm Orchestra BioMed closes $110 million Series D funding round, and plans to list on Nasdaq through venture of RTW-sponsored firm Health Sciences Acquisitions Corp 2.
Equity financing and business merger is expected to generate at least $180 million in proceeds, which will go toward funding the combined firm into 2026.
Current stock price: $1.00
12-month change: down 52%
Copyright 2022 Alliance News Limited. All Rights Reserved.
|
